MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

AbbVie Inc

Atvērts

SektorsVeselības aprūpe

205.82 -1.74

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

205.62

Max

211.94

Galvenie mērījumi

By Trading Economics

Ienākumi

-1.6B

-23M

Pārdošana

642M

15B

P/E

Sektora vidējais

87.887

73.239

EPS

2.16

Dividenžu ienesīgums

3.14

Peļņas marža

-0.152

Darbinieki

55,000

EBITDA

-4.4B

535M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+2.89% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

3.14%

3.06%

Nākamie ieņēmumi

2025. g. 25. apr.

Nākamais dividenžu datums

2025. g. 15. maijs

Nākamais Ex dividenžu datums

2025. g. 15. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

35B

369B

Iepriekšējā atvēršanas cena

207.56

Iepriekšējā slēgšanas cena

205.82

Ziņu noskaņojums

By Acuity

24%

76%

55 / 386 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

AbbVie Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 27. febr. 22:48 UTC

Iegādes, apvienošanās, pārņemšana

Mustang Bio to Exit Lease of Worcester, Mass. Manufacturing Facility

2025. g. 12. febr. 13:41 UTC

Galvenie tirgus virzītāji

Xilio Therapeutics Shares Surge Premarket on AbbVie Deal

2025. g. 31. janv. 13:28 UTC

Peļņas

AbbVie 4Q Revenue Tops Estimates as Skyrizi, Rinvoq Growth Surges

2025. g. 14. marts 09:30 UTC

Top Ziņas

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

2025. g. 3. marts 15:04 UTC

Iegādes, apvienošanās, pārņemšana

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. -- IBD

2025. g. 28. febr. 12:00 UTC

Top Ziņas

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

2025. g. 6. febr. 13:25 UTC

Top Ziņas
Peļņas

Bristol Myers Earnings Are a 'Tale of 2 Trends' as Guidance Falls Short. The Stock Is Falling -- Barrons.com

2025. g. 6. febr. 12:00 UTC

Peļņas

Bristol Myers Earnings Are 'a Tale of 2 Trends' as Guidance Falls Short -- Barrons.com

2025. g. 5. febr. 12:00 UTC

Top Ziņas

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

2025. g. 31. janv. 15:50 UTC

Top Ziņas
Peļņas

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

2025. g. 31. janv. 13:51 UTC

Peļņas

AbbVie Jumps After Its Powerhouses, Skyrizi And Rinvoq, Continued To Dominate -- IBD

2025. g. 31. janv. 13:47 UTC

Top Ziņas
Peļņas

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

2025. g. 31. janv. 13:24 UTC

Tirgus saruna
Peļņas

AbbVie Gets More Upbeat on Skyrizi, Rinvoq -- Market Talk

2025. g. 31. janv. 12:46 UTC

Peļņas

AbbVie's Stock Pops 4% After Earnings Beat Estimates And Company Offers Upbeat View Of 2025 -- MarketWatch

2025. g. 31. janv. 12:39 UTC

Peļņas

AbbVie 4Q Global Rinvoq Net Revenue $1.83B, Up 46.2% >ABBV

2025. g. 31. janv. 12:38 UTC

Peļņas

AbbVie: Expect 2025 Revenue to Exceed Previous Peak >ABBV

2025. g. 31. janv. 12:38 UTC

Peļņas

AbbVie Now Sees Aesthetics Delivering High-Single-Digit Compound Annual Revenue Growth From 2025-2029 >ABBV

2025. g. 31. janv. 12:37 UTC

Peļņas

AbbVie Raises 2027 Combined Sales Outlook for Skyrizi, Rinvoq to More Than $31B >ABBV

2025. g. 31. janv. 12:37 UTC

Peļņas

AbbVie Reaffirms Expectations for High-Single-Digit Compound Annual Revenue Growth Rate Through 2029 >ABBV

2025. g. 31. janv. 12:36 UTC

Peļņas

AbbVie: 4Q Revenue Rose 6.1% on Operational Basis >ABBV

2025. g. 31. janv. 12:36 UTC

Peļņas

AbbVie 4Q Loss $22M >ABBV

2025. g. 31. janv. 12:36 UTC

Peļņas

AbbVie 4Q U.S. HUMIRA Rev $1.25B >ABBV

2025. g. 31. janv. 12:36 UTC

Peļņas

AbbVie 4Q Global Net Rev From Oncology Portfolio $1.69B >ABBV

2025. g. 31. janv. 12:36 UTC

Peļņas

AbbVie 4Q Global Skyrizi Rev $3.78B >ABBV

2025. g. 31. janv. 12:36 UTC

Peļņas

AbbVie 4Q International HUMIRA Rev $436M >ABBV

2025. g. 31. janv. 12:36 UTC

Peļņas

AbbVie 4Q Adj EPS $2.16 >ABBV

2025. g. 31. janv. 12:36 UTC

Peļņas

AbbVie Sees FY Adj EPS $12.12-Adj EPS $12.32 >ABBV

2025. g. 31. janv. 12:36 UTC

Peļņas

AbbVie 4Q Loss/Shr 2c >ABBV

2025. g. 31. janv. 12:36 UTC

Peļņas

AbbVie 4Q Global IMBRUVICA Rev $848M >ABBV

2025. g. 31. janv. 12:36 UTC

Peļņas

AbbVie 4Q Rev $15.1B >ABBV

Salīdzinājums

Cenas izmaiņa

AbbVie Inc Prognoze

Cenas mērķis

By TipRanks

2.89% augšup

Prognoze 12 mēnešiem

Vidējais 215.57 USD  2.89%

Augstākais 240 USD

Zemākais 190 USD

Pamatojoties uz 16 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi AbbVie Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

16 ratings

12

Pirkt

4

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

201.34 / 209.52Atbalsts un pretestība

Īstermiņā

Weak Bearish Evidence

Vidējā termiņā

Bullish Evidence

Ilgtermiņā

Weak Bullish Evidence

Noskaņojums

By Acuity

55 / 386 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.